ClinicalTrials.gg
Drug

Lanreotide clinical trials

Also written Somatuline and Somatuline Depot.

studies test it
39
open now
2
in phase 3
17
first study started
2000

How each study uses lanreotide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the lanreotide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
30 Aug 2007 · SOMATULINE DEPOT · NDA 022074 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Lanreotide
18
lanreotide (Autogel formulation)
13
Lanreotide Autogel
3
lanreotide acetate
2
Ipstyl
2

Brand

Somatuline
8
Somatuline Depot
5
Somatuline Autogel
2

Development codes

BIM-23014
1
DC 13116
1

Other names

Angiopeptin
1

Studies by the year they started

39 studies that test it; most in 2017 (5)

Studies that test lanreotide, by start year
YearStudies
20002
20031
20042
20063
20073
20084
20094
20121
20131
20143
20154
20162
20175
20191
20201
20211
20251

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
3
Phase 2
21
Phase 3
17
Phase 4
6

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 19 · Other 20

Ipsen (19) · Radboud University Medical Center (2) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (2) · Antonio Fojo (1) · Assistance Publique - Hôpitaux de Paris (1) · Duke University (1) · Universitaire Ziekenhuizen KU Leuven (1) · Northwell Health (1)

Often tested with

Tested in the same studies.

Cabozantinib (2) · Pembrolizumab (1) · Temozolomide (1) · Metformin (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Lanreotide is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 2

Studies that test lanreotide.

Studies

Open first, then newest update. How each study uses lanreotide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 39

See all 39 studies that test lanreotide →

Given beside what is tested · 6 — lanreotide is usual care or a partner of the new treatment
As the comparator · 2 — what is tested is compared with lanreotide

Codes

What other systems call lanreotide · ClinicalTrials.gg INT003451

  • MeSH (NLM) C060347lanreotideConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 0G3DE8943YLANREOTIDEConfirmed FDA, NLM
  • RxNorm 68092One source FDA
  • NCI Thesaurus C1523LanreotideOne source FDA

Also registered as lanreotide acetate (UNII IEU56G3J9C · RxNorm 236167).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.